KH607 tablets

DRUG3 trials

Sponsors

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Conditions

Major Depressive Disorder (MDD)

Phase 2

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder

CompletedNCT07101120

Chengdu Kanghong Pharmaceutical Group Co., Ltd.Major Depressive Disorder (MDD)

Start: 2025-03-19End: 2026-02-09Updated: 2026-07-28

Phase 3

Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder

Not yet recruitingNCT07741331

Chengdu Kanghong Pharmaceutical Group Co., Ltd.Major Depressive Disorder (MDD)

Start: 2026-07-01End: 2028-12-01Target: 326Updated: 2026-08-03

A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder

Not yet recruitingNCT07741240

Chengdu Kanghong Pharmaceutical Group Co., Ltd.Major Depressive Disorder (MDD)

Start: 2026-07-01End: 2027-12-01Target: 232Updated: 2026-08-03